Oxidative stress is known to be a key factor in the pathogenesis of Parkinson's disease (PD). Neuronal redox status is maintained by glucose metabolism via the pentose-phosphate pathway and it is known that disruption of glucose metabolism is damaging to neurons. Accumulating evidence supports the idea that glucose metabolism is altered in PD and dysregulation of the pentose-phosphate pathway in this disease has recently been shown. In this review, we present an overview of the literature regarding neuronal glucose metabolism and PD, and discuss the implications of these findings for PD pathogenesis and possible future therapeutic avenues.
The relationship between oxidative stress and the mitochondria in neurons [16] . Iron has been shown to catalyse oxidation reactions in the presence of dopamine, which produces free radicals and subsequently tissue damage [17] . Increased extracellular iron levels in SNpc tissue of PD sufferers on autopsy [18] support the idea that dopamine may contribute to a higher oxidative stress load in dopaminergic neurons than in those that are non-dopaminergic. Thus, it has been suggested that oxidative stress could play a role in the formation of Lewy body pathology [19] .
Another important feature of neuronal degeneration in PD is the dysfunction of mitochondria. The synthetic opioid metabolite
1-methyl-4-phenylpyridinium ion (MPP+)
has been shown to selectively target the dopaminergic neurons of substantia nigra when injected intravenously [20] . On a cellular level, MPP+ causes decreased membrane potential and reduces oxidative phosphorylation due to Complex I damage [21] , with striking similarity to the Complex I damage which is also seen in PD post-mortem brain tissue [22] . Damage to other components of the respiratory chain, including complex IV (cytochrome c oxidase),
i.e. the target for astrocytic nitric oxide [23] has also been shown [24, 25] . Importantly, a study comparing glucose and oxygen metabolism in patients carrying mitochondrial DNA mutations, to PD patients, concluded that impaired mitochondrial functioning is not a primary insult in the pathogenesis of PD and that damage to the mitochondria may occur instead as a result of intracellular changes taking place [26] . Oxidised GSSG is recycled back to its reduced form by glutathione reductase.
Neuronal glucose metabolism and the pentose phosphate pathway
As discussed, neurons are normally exposed to high levels of ROS, possibly because their relatively high rate of oxidative phosphorylation and nitric oxide signaling from neighbor astrocytes [11] . in various brain regions, in both sporadic [31] and familial PD patients [32] . Similarly, it has also been shown that deep brain stimulation of the subthalamic nucleus in patients with advanced PD affects glucose metabolism [33] , supporting the idea that glucose homeostasis is tightly linked to the degenerative changes taking place in this disease. Measurement of glucose metabolites in the brains of PD patients has been shown increased levels of lactate [34] , and measurement of pyruvate in PD CSF has shown an increase in levels of the metabolite, accompanied by decreased levels of citrate, acetate, succinate and malate [35] . Together, these findings support the idea that overall alteration in glucose metabolism may be a feature of PD. On a cellular level, genetic microarray studies of the substantia nigra in PD show a strong association with the transcriptional regulator PGC-1α, which is involved in the control of glucose usage [36] .
Investigating possible links between glucose metabolism and PD has led to a number of reports that increasing glucose availability using glucagon-like-peptide (GLP) analogues is able to attenuate PD phenotypes on both a molecular and clinical level [37] . This has led to ongoing phase II clinical trials using the GLP-1 agonist exendin-4 (EXENATIDE-PD trial, NCT01971242), which are a positive step towards establishing a class of diseasemodifying drugs for PD.
The pentose-phosphate pathway in Parkinson's disease pathogenesis
Targeting the PPP in neuronal cell models has been shown to recapitulate many of the cellular phenotypes associated with PD, such as increased oxidative stress, mitochondrial damage, decreased GSH levels, and neuronal death [12] . Using L-buthionine sulfoximine to decrease total glutathione levels in rats, has shown that the increased oxidative stress that result from decreasing total GSH leads to damage of the respiratory chain complexes I and IV [38] . An important rodent study using pharmacological inhibition of the PPP to decrease NADPH levels globally produced a selective degenerative effect on dopaminergic neurons leading to motor deficits that resemble PD, such as bradykinesia [39] . This supports the idea that dopaminergic neurons are more sensitive than other neuronal subtypes to increases in ROS, but also highlights a possible mechanistic link between the PD and the PPP.
Given that neuronal glucose serves to produce NADPH for glutathione cycling, it is unsurprising that studies have shown decreased levels of GSH in the SN of PD patients. This decrease is thought to be up to 40% [40] . Similarly, reduced levels of GSH are also seen in brain tissue from individuals with incidental Lewy bodies, which is commonly thought to represent pre-symptomatic PD [41] .
In Alzheimer's disease brains, GSH levels are shown to be unchanged [42] . Importantly, it has been documented that protein levels of the PPP rate-limiting enzyme G6PD are increased in AD [43] , neuromuscular diseases [44] , myocardial infarction [45] , and in hepatocyte cell models [46] . Studies in post-mortem PD samples has shown that in early PD, NADPH production is not increased in the putamen and cortex, and that G6PD and 6PGD protein levels are conversely decreased in the putamen [10] . This suggests that PPP dysregulation could be an important mechanism in PD neurodegeneration. Interestingly, olfactory neurons, which have the highest PPP activity of all neuronal cell types in the brain [47] are among the first neurons to be involved in PD neurodegeneration [48] . Whether this is due to their dependence on the PPP, thus leaving them more vulnerable to changes in glucose flux through the PPP, remains to be elucidated.
In addition, studies examining the role of the PPP in other neurological disorders such as ALS and ataxia telangiectasia, suggest that downregulation of the PPP could be key factors in the neurodegenerative processes [49, 50] .
Taken together, these studies strongly support the idea that mitochondrial damage in PD is a knock on effect of a reduction in antioxidant reserve, and that impaired glucose metabolism is likely to be a key event in PD pathogenesis.
A role for α-synuclein in glucose regulation?
The role of α-synuclein (AS) in PD pathogenesis is an important, yet little understood mechanism. Many functions of α-synuclein have been suggested, including functioning as a ferrireductase [51] or in neurotransmitter release [52] ; however, there is currently little consensus on an exact role for this protein. Glucose deprivation in primary dopaminergic neurons and differentiated SH-SY5Y cells has been shown to cause AS aggregation and cell death [53] . Interestingly, AS-knockout mice show an upregulation of glucose metabolism and are protected against the mitochondrial damage caused by complex I inhibitor MPTP [54] . A recent study has suggested that glucose uptake may be controlled by α-syn signalling via the LPAR2/ Gab1/PI3K/Akt pathway [55] . Importantly, MPTP toxicity is mediated through nitric oxide from inducible nitric oxide synthase [56] and knockout of the human SNCA gene in neuronal cultures confers protection against nitric oxidemediated toxicity [57] . It has been shown that AS is able to activate nitric oxide synthase in rats [58, 59] . Inhibition of mitochondrial cytochrome c oxidase by nitric oxide causes upregulation of glycolysis [23, 28] and the PPP [60] , and nitric oxide has been shown to control the balance of glucose metabolism between these two pathways [61] . As such, these studies suggest that there may be either a direct or an indirect functional link between AS and nitric oxide, and that AS may exert some control over glucose metabolism in the brain. If this is the case, further investigation into these links may lead to the opening of important therapeutic avenues for PD in the future.
Conclusions
In conclusion, there are clear links between PD and neuronal glucose metabolism, PPP activity, and oxidative stress. Increased oxidative stress is implicated in the pathogenesis of PD.
We propose that that PPP dysfunction and perturbed glucose metabolism are early events in the etiology of PD and hypothesise that dysregulation of the PPP in PD is a key event in neurodeneration (Fig. 2) .
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